Triastek, Inc.

Triastek, Inc. is a global healthcare and pharmaceutical company that specializes in developing and manufacturing medicines using proprietary 3D printing technology.

Founded in July 2015 by Dr. Senping Cheng and Dr. Xiaoling Li, Triastek is recognized as the first specialized 3D printing pharmaceutical company in China and is the only China-based company selected for the U.S. FDA Emerging Technology Program. The company is headquartered in Nanjing, China, with additional operational centers for research and production. Triastek offers a range of services centered on its 3D printing technology platform, including dosage form design, digital pharmaceutical product development, and intelligent manufacturing. The company has developed three 3D-printed drugs, all of which have received Investigational New Drug (IND) clearance from the FDA. Triastek's innovative Melt Extrusion Deposition (MED®) process allows for the creation of complex drug structures with controlled release, positioning the company as a leader in intelligent pharmaceutical manufacturing.